After a controversial court case five years ago in India, drug makers were put on notice that additional patents on medicines would have to demonstrate a degree of innovation. But a new analysis finds the vast majority of so-called secondary patents were granted for only marginal improvements, raising questions about the extent to which companies are adding value to their drugs.

Specifically, 72 percent of granted patents were found to offer little improvement and the findings suggest the Indian Patent Office is failing to guard against evergreening, a strategy for extending the market exclusivity of a prescription drug in order to delay the entry of generic versions, according to the analysis by Accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy